Kite, A Gilead Company, Says FDA Approved Label Update For Yescarta CAR T-Cell Therapy To Include Overall Survival Data
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved a label update for Yescarta, a CAR T-cell therapy by Kite, a Gilead Sciences subsidiary. The update includes overall survival data from the ZUMA-7 study, showing a 27.4% reduction in the risk of death and a 38% improvement in overall survival (OS) compared to the standard of care (SOC).
December 21, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences' subsidiary Kite has received FDA approval for a label update on Yescarta, indicating significant improvements in patient survival rates.
The FDA approval for the label update of Yescarta is likely to be viewed positively by investors and could lead to increased confidence in Gilead Sciences' product portfolio. The inclusion of overall survival data is a strong endorsement of the therapy's efficacy, which may enhance its marketability and potentially lead to increased sales. This news directly impacts Gilead Sciences and is highly relevant to the company's performance in the biotechnology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100